Dhruti Patel, MD
Urology · Saint Louis, MONPI 1407172877
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.0%), travel and lodging and other — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Intuitive Surgical at 28.9% of the total. Reporting peaked in 2021 at $3,207 and has fallen 95.3% since, to $152 in 2025.
Across 131 payments — averaging $92.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Boston Scientific$2K
- Teleflex LLC$2K
- EDAP Technomed Inc$2K
- Endo Pharmaceuticals Inc.$273
- AbbVie$266
- plus $2K from 15 others
What the payments were for
- Travel & lodging$4,37236%
- Food & beverage$5,09442%
- Education$1301%
- Gifts$230%
- Other$2,50021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $3,503 |
| Boston Scientific | 24 | $2,347 |
| Teleflex LLC | 15 | $2,312 |
| EDAP Technomed Inc | 24 | $1,900 |
| Endo Pharmaceuticals Inc. | 5 | $273 |
| AbbVie(2 entities) | 6 | $266 |
| Medtronic | 2 | $237 |
| C. R. Bard, Inc. & Subsidiaries | 12 | $165 |
| Astellas Pharma US Inc | 5 | $161 |
| Neotract Inc. | 1 | $142 |
| Coloplast | 3 | $131 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Urovant Sciences Inc | 4 | $100 |
| Bayer | 1 | $92 |
| Sumitomo Pharma America, Inc. | 3 | $88 |
| Blue Earth Diagnostics | 4 | $86 |
| Axonics, Inc. | 1 | $78 |
| Zyla Life Sciences, Inc. | 3 | $50 |
| Pfizer | 1 | $24 |
| Travere Therapeutics, Inc. | 7 | $23 |
| Tolmar, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,380
- UroLift$1,781
- GENERAL KIDNEY STONE DISEASE$847
- Moses 550 D\F\L$739
- UroLift System$290
- XIAFLEX$236
- INTERSTIM ICON$172
- BOTOX$136
- Erleada$121
- AMS$116
- LithoVue$111
How this compares
$12,120 in reported general payments places this provider in the 85th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 55 | $32,871 |
| GemtesaVibegron | 36 | $29,510 |
| Estradiol | 96 | $4,954 |
| Tamsulosin Hcl | 135 | $2,913 |
| Trospium Chloride | 17 | $1,680 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,474 |
| Finasteride | 58 | $481 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $175 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $131 |
| Cefdinir | 14 | $130 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $93 |
| Cephalexin | 28 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $161 | $32,87155 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $88 | $29,51036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 urology providers in Missouri.
Other urology in Saint Louis
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Gurdarshan SandhuSaint Louis$101K
- Gregory McLennanSaint Louis$89K
- Gerald AndrioleSaint Louis$64K
- Charles JonesSaint Louis$55K
- Meredith MetcalfSaint Louis$26K
- Maung Htein ThuSaint Louis$22K
- Alexander ChowSaint Louis$20K
- Jonathan WeeseSaint Louis$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.